×
About 657,158 results

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
https://doi.org/10.1002/art.41752
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

Fluconazole - fluconazole tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11e0926-cd15-49ba-b0ee-2b6d4e009dd8

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

Quetiapine fumarate - quetiapine fumarate tablet, extended release-Lupin Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7803a290-91c0-4e7f-90b5-d2ff33a46cee

Jun 1st, 2022 - Quetiapine extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3) Quetiapine extended-release tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine ext...

Imatinib mesylate - imatinib mesylate tablet, film coated-Apotex Corp
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509

May 30th, 2022 - Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon...

Optimization of therapy in patients with epilepsy and psychiatric comorbidities: key po...
https://doi.org/10.2174/1570159X20666220526144314
Current Neuropharmacology; Pisani F, Rosa Pisani L et. al.

May 28th, 2022 - Psychiatric disorder comorbidity in patients with epilepsy (PWE) is very frequent with a mean percentage prevalence of up to 50% and even higher. Such a high frequency suggests that epilepsy and psychiatric disorders might share common pathological pathways. Various aspects contribute to make the matter very complex from a therapeutic point of view. Some antiseizure medications (ASMs), namely v...

Application of the CT/MRI LI-RADS Treatment Response Algorithm to Contrast-Enhanced Ult...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128751
Journal of Hepatocellular Carcinoma; Ruan SM, Cheng MQ et. al.

May 28th, 2022 - The contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (TRA) is still in development. The aim of this study was to explore whether the CT/MRI LI-RADS TRA features were applicable to CEUS in evaluating the liver locoregional therapy (LRT) response. This study was a retrospective review of a prospectively maintained database of patie...

Breathing in Duchenne muscular dystrophy: Translation to therapy.
https://doi.org/10.1113/JP281671
The Journal of Physiology; Mhandire DZ, Burns DP et. al.

May 28th, 2022 - Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease caused by a deficiency in dystrophin - a structural protein which stabilizes muscle during contraction. Dystrophin deficiency adversely affects the respiratory system leading to sleep-disordered breathing, hypoventilation, and weakness of the expiratory and inspiratory musculature, which culminate in severe respiratory dysfu...

Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in a...
https://doi.org/10.1080/14656566.2022.2082283
Expert Opinion on Pharmacotherapy; Dierickx D, Neefs J

May 28th, 2022 - Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by increased platelet destruction and decreased platelet production, leading to thrombocytopenia with or without bleeding manifestations. The majority of patients experiencing treatment need will eventually need secondary treatment following first line therapy with steroids. In 2018, the oral spleen tyrosine kinase i...

Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient a...
https://doi.org/10.3390/curroncol29050239
Current Oncology (Toronto, Ont.); Nemeckova S, Alexova-Zurkova K et. al.

May 28th, 2022 - Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to the re-localization of the NPM1 protein from the nucleolus to the cytoplasm (NPM1c+). NPM1c+ is found in 30% of acute myeloid leukemia (AML). Our stu...

Immune Checkpoint Inhibitors in Cancer Therapy.
https://doi.org/10.3390/curroncol29050247
Current Oncology (Toronto, Ont.); Shiravand Y, Khodadadi F et. al.

May 28th, 2022 - The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and non-small lung cancer. The US FDA has succ...

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma.
https://doi.org/10.3390/curroncol29050278
Current Oncology (Toronto, Ont.); Risinskaya N, Mangasarova Y et. al.

May 28th, 2022 - Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin's lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration ...

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutatio...
https://doi.org/10.3390/curroncol29050285
Current Oncology (Toronto, Ont.); Rekowska A, Rola P et. al.

May 28th, 2022 - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80-85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)-40-50% and squamous cell carcinoma (SCC)-20-30%. The development of new molecular therapies targeting particular abnormalities such as mutati...

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
https://doi.org/10.3390/curroncol29050293
Current Oncology (Toronto, Ont.); Todorovic Z, Todorovic D et. al.

May 28th, 2022 - Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possi...

De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cel...
https://doi.org/10.3390/curroncol29050295
Current Oncology (Toronto, Ont.); Silver JA, Turkdogan S et. al.

May 28th, 2022 - The prevalence of oropharyngeal squamous cell carcinoma has been increasing in North America due to human papillomavirus-associated disease. It is molecularly distinct and differs from other head and neck cancers due to the young population and high survival rate. The treatment regimens currently in place cause significant long-term toxicities. Studies have transitioned from mortality-based out...

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Live...
https://doi.org/10.3390/curroncol29050290
Current Oncology (Toronto, Ont.); Abdelrahim M, Al-Rawi H et. al.

May 28th, 2022 - The management of cholangiocarcinoma is continually reviewed on a current evidence basis to develop practice guidelines and consensus statements. However, the standardized treatment guidelines are still unclear for cholangiocarcinoma patients who are listed for liver transplantation. We aimed to validate and evaluate the potential efficacy of chemotherapy combination of Gemcitabine and Cisplati...

A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generaliz...
https://doi.org/10.4088/PCC.AR21018WC2C
The Primary Care Companion for CNS Disorders; Bril V, Silvestri NJ et. al.

May 28th, 2022 - Generalized myasthenia gravis (gMG) is a disease resulting from impaired neuromuscular transmission due to presence of antibodies that block acetylcholine receptors. Autoantibodies to acetylcholine receptors directly impair the activity of ion channels that conduct nerve impulses, and cross-link acetylcholine receptors resulting in complement-mediated destruction, further worsening functional i...

6 and 12-Month Outcomes After 90:10 Enteral Nutrition Induction Therapy in Pediatric Cr...
https://doi.org/10.1097/MPG.0000000000003475
Journal of Pediatric Gastroenterology and Nutrition; Davidson N, Rutsky J et. al.

May 28th, 2022 - Studies describing longer-term outcomes after EEN induction are limited. We describe clinical outcomes during 90:10 EN induction, and 6- and 12- month outcomes among patients that successfully completed EN induction and then continued either EN or immunomodulator (IM) maintenance therapy. All children with CD treated with 90:10 EN induction protocol (90% formula:10% regular diet) at our IBD Cen...

AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features an...
https://doi.org/10.1080/16078454.2022.2078027
Hematology (Amsterdam, Netherlands); Assaf N, Lefebvre C et. al.

May 28th, 2022 - Acute myeloid leukemia (AML) with inv(16)/t(16;16) is among the most frequent AML subtypes. It is recognized by the detection of the CBFB-MYH11 fusion which confers a favorable prognosis, irrespective of the presence of secondary cytogenetic abnormalities. However, the effect of additional genetic anomalies on the behavior of inv(16) AML is debatable. Recent case reports describe an unfavorable...

Bone Remodeling in a Mps-1h Girl after Hematopoietic Stem Cell Transplantation along wi...
https://doi.org/10.2174/1871530322666220520121839
Endocrine, Metabolic & Immune Disorders Drug Targets; Tummolo A, Brunetti G et. al.

May 28th, 2022 - Background Mucopolysaccharidosis-1H (Hurler syndrome, MPS-1H) is the most severe form of a lysosomal storage disorder (LSD) caused by variants in IDUA, encoding alpha-L-iduronidase (IDUA). MPS-1H is also associated with various degree of skeletal defects due to the accumulation of partially degraded glycosaminoglycans (GAGs) in the lysosomes of connective tissue cells. The efficacy of hematopoi...

Risk of tuberculosis infection and serial changes in interferon-gamma release assays in...
https://doi.org/10.1111/1346-8138.16471
The Journal of Dermatology; Koo T, Baek G et. al.

May 28th, 2022 - Elderly patients constitute a significant proportion of patients with psoriasis. Nonetheless, treatment for older patients is more challenging than that for younger ones. Biologic agents are preferable to other systemic drugs for elderly patients with moderate-to-severe psoriasis owing to their high efficacy and favorable tolerability. However, there are limited data on tuberculosis infection r...